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Summary
Background: Methadone remains the mainstay pharmacotherapy for heroin dependent women across Europe although 
treatment is not standard and neonatal outcomes vary. Aim: We studied pregnant opioid dependent women to compare 
outcomes during the peri- and postnatal period in infants exposed to methadone in utero. We hypothesized that doses 
<30 mg methadone/day would contribute to poorer infant outcomes when compared to doses ≥30 mg methadone/day. 
Methods: A retrospective case note study of methadone maintained mother and infant pairs were evaluated. Cases from 
an inner city Specialist NHS Substance Misuse Service were categorized according to the methadone dose received at 
delivery: ≤ 30 mg (detoxification dose) or >30 mg methadone/day. Infant outcomes included gestation, birth weight, and 
mode of delivery, prevalence of Neonatal Withdrawal Syndrome (NAS) and parenting. Results: Nearly twice as many 
infants in the ‘≤ 30 mg’ group were treated for NAS (40% Vs 22.7% respectively). Mothers in the >30 mg’ group were 
significantly more likely to use; crack cocaine (59.1% Vs 20%, p < 0.044); drugs by the intravenous route (49.1% Vs 
6.7%, p < 0.054) and; be referred to Social Services (100% Vs 73%, p < 0.043). Half of their infants were placed under 
protective care. Conclusions: Our study suggests differences in outcomes for infants according to the maternal dose at 
delivery. More detailed assessment during pregnancy and in the perinatal period of the addict lifestyle may be crucial in 
optimising neonatal outcomes. Further research is needed in this area.
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1. Introduction
An estimated 30,000 pregnant women are said 
to use illicit opioids each year in the European Union 
[10] but prevalence data is often unavailable or col-
lected in such a way as to make comparisons difficult 
[24]. In Spain 16% of mothers giving birth had used 
illicit drugs during the third trimester of their preg-
nancy although only 2% of the mothers had reported 
drug use during their pregnancy [9], whereas in the 
Czech Republic a prevalence of 1.8% illicit drug use 
was reported among mothers delivering between 2000 
and 2009 [24]. In the UK, according to the Advisory 
Council on the Misuse of Drugs there are between 
250,000 and 350,000 children born to substance mis-
using parents [11]. 
Opioid drug use during pregnancy is associated 
with both adverse maternal and neonatal outcomes: 
maternally including absence of adequate prenatal 
care and increased risk of contracting blood born vi-
ral infections; as a neonate suffering low birth weight 
[14] symptoms of neonatal abstinence [1, 8, 29], and 
possible impact on childhood development [20, 21]. 
Methadone maintenance treatment (MMT) dur-
ing pregnancy has been extensively studied and is still 
considered to be the gold standard treatment [7, 15, 
22, 27]. The United States, Australia and the UK cite 
MMT as the best treatment for pregnant substance 
misusing mothers [23]. It has been demonstrated that 
methadone on a fixed-daily dose reduces illicit sub-
stance use and improves prenatal care, neonatal out-
come, and the overall health of pregnant women [25]. 
However, the benefits can be obviated if inadequate 
methadone dose is prescribed and heroin is also used 
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[14].
The purpose of this study was to compare out-
comes in infants exposed to different doses of metha-
done in utero. We hypothesized that doses ≤ 30 mg (at 
or below the dose commonly used to initiate detoxi-
fication) methadone/day compared to doses > 30 mg 
methadone/day would contribute to poorer outcomes 
for infants. 
2. Methods
2.1. Study Design and Subjects
A total of 167 pregnant women were identi-
fied retrospectively from case notes accessed from 
a UK inner city NHS specialist drug treatment ser-
vice. Conditions for inclusion in the study included 
meeting Diagnostic and Statistical Manual of Men-
tal Disorders (DSM-IV), Revised Fourth Edition [4] 
criteria for opiate dependence, pregnancy and being 
older than 18 years of age. To minimise confounding, 
inclusion was limited to women taking a single daily 
dose of methadone, with singleton pregnancies, who 
had been prescribed methadone for at least one month 
and who delivered at least 24 weeks of gestation. 
Thirty-seven cases met the study criteria (Figure 1). 
To facilitate comparisons, cases were stratified 
according to the daily dose of methadone prescribed 
at delivery, namely ≤ 30 mg/day and > 30 mg/day. 
The rationale for this split was based on the use of 
this stratification to classify drug use in similar earlier 
research and national clinical prescribing guidelines 
related to the recommended dose to begin detoxifica-
tion [5, 6].
2.2. Ethical approval
This study was approved by the Joint South 
London and Maudsley NHS Foundation Trust and 
Institute of Psychiatry, Psychology & Neuroscience 
(IoPPN)King’s College London Research Ethics 
Committee. 
2.3. Instruments
Data was collected on general demographics, 
detailed social and familial circumstances, and deliv-
ery and birth outcomes. The Rivers Scale was used to 
score neonatal abstinence syndrome (NAS) [26].
2.4. Data analysis
The independent sample t-test for continu-
ous data and chi-squared test for categorical data 
was used to examine dose group differences for all 
demographic and clinical variables. Logistic regres-
sions were performed in order to examine whether 
there was an independent effect of methadone dose 
on maternal and neonatal outcomes after controlling 
for background variables. Statistical significance was 
set at p < 0.05 for all analyses. However, given the 
small sample size associated with this initial study 
other levels of significance were also reported. All p 
values were 2-tailed with corrections for small num-
bers where p < 0.05. 
3. Results
3.1. Demographics and methadone maintenance 
treatment
The mean age of the 37 cases included in the 
study was 30.2 ± 5.4 years; the majority (76%) of 
these women were white Caucasian women and 59% 
lived in unstable accommodation i.e. hostel, or tem-
porary housing. The women were prescribed wide 
ranging doses of methadone (range 10 mg – 135 mg 
methadone/day). The daily dose of methadone was 
not fixed for the duration of pregnancy. The mean 
167 pregnant women 
enrolled in methadone 
maintenance programme 
37 cases were identified as 
matching the inclusion criteria 
22 cases were included in the 
High Dose Group: prescribed 
>30mg methadone/day at
delivery
15 cases were included in the 
Low Dose Group: prescribed 
≤30mg methadone/day at 
delivery
37 infants delivered and 
considered in the study
126 pregnant women 
attended an initial 
appointment
105 cases were opioid 
dependent
Figure 1. Flow chart of study participants
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dose at initial assessment was 44.7 mg methadone/
day; the mode 30 mg/day, prescribed to 18.9% of 
the group (range 10 mg – 115 mg methadone/day). 
At delivery, this pattern of dosage had changed. The 
mean dose had reduced to 38.4 mg methadone/day 
with the highest dose being 80 mg (range 10 mg – 80 
mg) methadone/day: 2 women were detoxified from 
methadone. Fifteen cases were prescribed ≤ 30 mg 
methadone/day at delivery compared to 13 women 
at the initial assessment. Eighteen women (48.6%) 
underwent methadone dosage reduction during preg-
nancy, 11 (11%) remained on the same fixed daily-
dose and 8 (8%) had their daily dose increased. There 
was an overall trend towards methadone dosage re-
duction in the period between initial assessment and 
delivery, and no relation between change in dose and 
outcome variable.
3.2. Dosing (≤ 30 mg versus ≥30 mg methadone/day) 
characteristics 
There were few significant differences between 
the ˃30 mg dose and the ≤ 30 mg methadone dose 
groups except in relation to drug use behaviour (Table 
1). The ˃30 mg dose group were more likely to be 
prescribed benzodiazepines and there was evidence 
that they were more likely to use drugs via the intrave-
nous route (49.1% Vs 6.7%, respectively; p < 0.054). 
In addition, from the toxicology results recorded from 
urine drug screening it was found that crack cocaine 
use was significantly more common among mothers 
in the ≥30 mg dose group than the ≤ 30 mg dose group 
(59.1% Vs 20%, respectively; p < 0.044). 
3.3. Neonatal and perinatal outcomes 
The mean gestational age of the neonates was 
35.2 ± 3.4 weeks, with 23.7% weighing <2.5kg and 
characterized as premature. There were more prema-
ture infants in those prescribed >30 mg methadone/
day, but otherwise growth parameters were simi-
lar between the two groups (Table 2). There was no 
difference in the mean birth weight of infants when 
dose at delivery was compared (2.9 kg for ≤ 30mg 
Vs 2.7 kg for > 30 mg methadone/day, respectively) 
more ‘low-weight-for-date’ infants in the ≤ 30mg 
dose group (80% Vs 68.2%, respectively). Although 
infants in this cohort were almost twice as likely to 
receive pharmacotherapy for NAS when the mater-
nal dose of methadone at delivery was below 30 mg 
methadone/day (40% Vs 22.7%, respectively), this 
did not approach statistical significance (Table 3).
3.4. Postnatal care
When baseline characteristics were controlled, 
there was no effect of delivery dose on gestation-
al age, type of delivery, birth weight or whether or 
not the infant was treated in a special care baby unit 
(SCBU). However, there was some suggestion that 
women who were living in stable accommodation 
and prescribed higher doses of methadone were more 
likely to have full term delivery. Most of the cases 
(86%) had a community-based health visitor involved 
in their postnatal care and more than half were seen 
at home by a midwife (52%). Nevertheless 38% of 
infants were placed under protective order (regis-
Table 1. Comparison of Maternal and Socioeconomic Parameters for the High and Low Dose Methadone 
Groups
Low Dose Group
N=15
High Dose Group
N=22 p
n (%)
M±sd
n (%)
M±sd
Maternal age 31.9±6.3 28.5±4.5 0.059
Ethnicity (white) 13 (86.7) 15 (68.2) 0.198
Registered with physician 14 (93.3) 21 (95.5) 0.779
Unstable accommodation 9 (60.0) 13 (59.1) 0.956
Care of children 7 (46.7) 8 (36.4) 0.531
Illicit drug use
Crack cocaine 3 (20.0) 13 (59.1) 0.044*
Prescribed medication 1 (6.7) 4 (18.2) 0.314
Intravenous drug use 1 (6.7) 9 (40.9) 0.054*
Hepatitis C antibody positive 5 (33.3) 5 (22.7) 0.476
Unstable accommodation included hostels, temporary shelter or homelessness
Care of children referred to parental responsibility for other children under 16 years of age
Prescribed medication refers to benzodiazepines (usually diazepam)
* Chi-square with Yates correction for small numbers
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tered with a Child Protection Agency) and 26% were 
discharged into the care of foster parents (Table 2). 
Women in the ‘>30mg Dose’ group at delivery were 
significantly more likely to be referred to Social Ser-
vices (100% Vs 73%, respectively p < 0.043).
4. Discussion
In this retrospective case-note study 37 pregnant 
women who had been maintained on methadone were 
investigated. When baseline characteristics were con-
trolled, there was no effect of delivery dose on gesta-
tional age, type of delivery, birth weight or whether 
or not the infant was treated in a SCBU. Cases were 
split into those prescribed ≤ 30 mg/day versus those 
prescribed ˃30 mg methadone/day at delivery. It is 
widely accepted that high-dose MMT provides a 
‘blockade against other opioids such as heroin during 
pregnancy and has a positive effect on maternal illicit 
drug use' [2, 6, 18-19]. 
The mean dose at initial assessment in our co-
hort was 44.7 mg and at delivery 38.4 mg methadone/
day, too low to achieve a blockade effect and thus al-
though preventing withdrawal our cases continued to 
use illicit drugs by high-risk routes. The variability 
in dosing schedules observed in our cases however is 
not unusual and has been reported in other methadone 
maintained pregnant populations [23]. 
Infants in the ˃30 mg methadone/day group 
had poor social and familial postnatal outcomes. All 
mother and infant pairs were referred to Social Ser-
vices: half of the infants being placed under protective 
order and 32% removed from their biological mother. 
It has been shown that children of drug-dependent 
mothers in foster care have less favourable outcomes 
compared with those living with their biological par-
ents [16-17]. A further complicating factor was that 
a large proportion of our cases had dependents under 
Table 2 Comparison of Maternal and Infant Parameters for the High and Low Dose Methadone Groups
Low Dose Group
N=15
High Dose Group
N=22 p
n (%)
M±sd
n (%)
M±sd
Gestation
Full Term (> 36 weeks) 12 (80.0) 16 (72.7) 0.613
Mode of delivery
Vertical (SVD) 10 (66.7) 18 (81.8)
Other (ECS, CS) 5 (33.3) 4 (18.2) 0.292
Neonatal outcome
Birth weight (Kg) 2.95±0.47 2.67±0.72 0.206
Premature birth 3 (20) 6 (27.3)
Premature birth weight (kg)
<2.5kg) 12 (80.0) 15 (68.2) 0.427
Attended SCBU 4 (26.7) 6 (27.3) 0.967
Infant treated for NAS 6 (40.0) 5 (22.7) 0.259*
Breast feeding occurred 8 (53.3) 10 (45.5) 0.638
Postnatal period
Midwife seen 8 (53.3) 11 (50.0) 0.842
Health visitor involved 12 (80.0) 20 (90.9) 0.341
Referred to Social Services 11 (73.3) 22 (100.0) 0.043*
Placed on CPR 4 (26.7) 11.50.0) 0.156
Infant removed from parent§ 3 (20.0) 7 (31.8) 0.427
Stable accommodation 8 (53.5) 14 (63.6) 0.531
SVD – Spontaneous Vertical Delivery
ESC – Emergency Caesarean Section; CS – Caesarean Section
SCBU – Special care baby unit
NAS – Neonatal abstinence syndrome
CPR – Child Protection Register
§When a child is deemed to be at risk, social services can remove the infant from the parent and place the child in the care 
of the state with foster parents
*Chi-square with Yates correction for small numbers
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the age of 16 years: nearly half of the women were 
responsible for progeny < 16 years of age (46.7% ≤ 
30 mg/day dose group vs 36.4% ˃ 30 mg/day dose 
group, respectively). This is an important complica-
tion that requires further investigation [12]. It has 
been reported that the development of strong patient-
provider relationships can improve health care during 
pregnancy [3].
In our ‘> 30 mg/day dose' group we found evi-
dence of continuing illicit drug use (cocaine) and in-
travenous drug use, both of which have been shown to 
indicate high risk behaviour and potentially a reduced 
capacity to care for small children [28]. However, the 
situation is complicated with evidence from Hulse et 
al [13] in a meta-analysis that the life-styles associ-
ated with illicit drug use during pregnancy rather than 
illicit drug use per se may be the primary risk factor 
for successful infant outcomes.
4.1. Limitations
As with other retrospective studies, certain limi-
tations are unavoidable and need mention. The pri-
mary limitation of this study is the sample size, as 
only 37 pregnant women were eligible for the study; 
this limited the interpretation of any association be-
tween groups. A larger sample size would be neces-
sary to explore any significant or suggestive findings. 
Tobacco and alcohol use history were not universally 
documented. These could also have an impact on the 
results of the outcome measures.
5. Conclusions
More research is needed in this area and should 
concentrate on both methadone treatment as well as 
life-style factors as important variables for women 
and infants in the post-natal period. Health care pro-
viders should advocate approaches informed by sci-
entific research and evidence-based practice to opti-
mise outcomes for mothers and their neonates [29].
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